• New data presented at Transcatheter Cardiovascular Therapeutics (TCT) 2023 from the TRILUMINATE™ pivotal trial confirm safety, effectiveness and improvements in quality of life when treating tricuspid regurgitation (a leaky valve) with TriClip™, an investigational device in the U.S.
• One-year outcomes from the EXPAND G4 study, simultaneously published in JACC: Cardiovascular Interventions, reinforce durable safety and effectiveness of MitraClip™ with significant mitral regurgitation reduction

ABBOTT PARK, Ill., Oct. 24, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced data from late-breaking presentations showing the impact of its minimally invasive heart devices in treating mitral and tricuspid valve disease. Data include findings from the TRILUMINATE™ pivotal trial that reinforce the safety and effectiveness of the TriClip™ transcatheter edge-to-edge repair (TEER) system for patients with symptomatic, severe tricuspid regurgitation (TR) despite optimal medical therapy.